<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02275702</url>
  </required_header>
  <id_info>
    <org_study_id>APV-100</org_study_id>
    <nct_id>NCT02275702</nct_id>
  </id_info>
  <brief_title>Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients</brief_title>
  <acronym>APV</acronym>
  <official_title>Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a randomized, double-blind, placebo-controlled evaluation if a small
      dose of IV dexamethasone during induction anesthesia in association to pre and postoperative
      intercostal nerve block, improves quality of recovery of thoracoscopic lung resection
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study composed by 2 groups of 50 patients undergoing VATS for lung cancer. All
      subjets will receive intraoperative intercostal nerve block with a maximum dose of 2 mg/kg of
      bupivacaine with epinephrine 1:200.000 at the beginning and at the end of procedure.

      The control group will receive a bolus dose of dexamethasone (0.1 mg/kg) and the placebo
      group saline solution. The study drug or placebo will be administered at the time of
      anesthetic induction (approximately 30 minutes before surgical incision). Patients will be
      evaluated daily with the quality of recovery questionary, visual analogue pain and portable
      spirometry. And, the patients will have pulmonary lung function assessed by portable
      spirometry.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome of this study will be postoperative quality of recovery measured by postoperative quality of recovery score 40 (QoR-40) global score.</measure>
    <time_frame>During the hospital stay and 1 year later</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of analgesia between the final intercostal nerve block and the first patient-controlled analgesia (PCA) request;</measure>
    <time_frame>During the hospital stay and 1 year later</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation between pain with visual analog scale and lung function through spirometry test with forced expiratory volume at one second (FEV1) and diffusion capacity (DLCO)</measure>
    <time_frame>During the hospital stay and 1 year later</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total opioid dose consumption in each group</measure>
    <time_frame>During the hospital stay and 1 year later</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Side-effect of dexamethasone in the stress response to surgery</measure>
    <time_frame>During the hospital stay and 1 year later</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>- Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline solution IV, bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0,1mg/kg systemic dose of dexamethasone, bolus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone IV</intervention_name>
    <description>It will be administered at the induction of the anesthesia</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  resectable stage I and II lung cancer patients submitted to VATS

          -  american society of anesthesiology Classification (ASA) I or II

        Exclusion Criteria:

          -  chronic pain;

          -  chronic analgesic consumption;

          -  severe renal or liver disease;

          -  endocrine or mental diseases;

          -  poorly controlled diabetes;

          -  allergy to bupivacaine;

          -  previous thoracotomy;

          -  systemic use of corticosteroids;

          -  morbid obesity;

          -  poor French comprehension precluding completion of the QoR-40 questionnaire;

          -  patient refusal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula A. Ugalde, Medicin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Universitaire de Cardilogie et Pneumologie de Québec, IUCPQ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guilherme Dal Agnol, Fellowship</last_name>
    <phone>+14185707295</phone>
    <email>guilherme.dal.agnol@criucpq.ulaval.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Québec, IUCPQ</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1v 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guilherme Dal Agnol, Fellowship</last_name>
      <phone>+14185707295</phone>
      <email>guilherme.dal.agnol@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Paula A Ugalde, Medicin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Bussières, Medicin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves Lacasse, Medicin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guilherme Dal Agnol, Medicin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie Gagné, Nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCPQ</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V3H8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guilherme Dal Agnol, fellow</last_name>
      <phone>4185707295</phone>
      <email>guilherme.dal.agnol@criucpq.ulaval.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexamethasone</keyword>
  <keyword>Quality of recovery questionnaire</keyword>
  <keyword>QoR-40</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Video-assisted thoracoscopic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

